Wechselwirkungen von Zolmitriptan

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Amfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (Fachinformation zu Amfetamin und Dexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Belladonna und Opium, Arzneimittelwechselwirkungen)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (Fachinformation zu Buspiron, Warnhinweise)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Arzneimittelwechselwirkungen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Arzneimittelwechselwirkungen)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Butorphanol, Vorsichtsmaßnahmen)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Codein, Arzneimittelwechselwirkungen)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (Fachinformation zu Cyclobenzaprin, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant use of Monoamine Oxidase Inhibitors (MAOIs) and serotonergic drugs may potentially cause life threatening adverse events ( see CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION ). (Fachinformation zu Desipramin, Arzneimittelwechselwirkungen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (Fachinformation zu Dexamfetamin, Warnhinweise)

…hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that… (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Granisetron, Warnhinweise und Vorsichtsmaßnahmen)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Ibuprofen, Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Hydrocodon und Paracetamol, Vorsichtsmaßnahmen)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Levorphanol, Vorsichtsmaßnahmen)

• Serotonin Syndrome: Monitor patients taking Linezolid injection concomitantly with serotonergic agents for signs of serotonin syndrome. (Fachinformation zu Linezolid, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Lisdexamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Fachinformation zu Lithium, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (Fachinformation zu Zolmitriptan, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (Fachinformation zu Mirtazapin, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Fachinformation zu Morphin, Arzneimittelwechselwirkungen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Ondansetron, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (Fachinformation zu Palonosetron, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Paracetamol und Codein, Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Fachinformation zu Pentazocin und Naloxon, Vorsichtsmaßnahmen)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Pethidin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Fachinformation zu Promethazin und Codein, Arzneimittelwechselwirkungen)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Remifentanil, Warnhinweise und Vorsichtsmaßnahmen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 ) (Fachinformation zu Zolmitriptan, Gegenanzeigen)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fachinformation zu Tapentadol, Warnhinweise und Vorsichtsmaßnahmen)

These medicines are in some cold, hay fever or weight-loss medicines. sympathomimetic herbal medicines or dietary supplements antihistamines (allergy medicines) triptans buspirone carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazin… (Fachinformation zu Tranylcypromin, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors Cases of life-threatening serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions ( 5.7 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

If cimetidine and zolmitriptan are used concomitantly, limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in any 24-hour period [see Dosage and Administration, ( 2.4 ) and Clinical Pharmacology ( 12.3 ) ]. (Fachinformation zu Zolmitriptan, Arzneimittelwechselwirkungen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (Fachinformation zu Droxidopa, Arzneimittelwechselwirkungen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (Fachinformation zu Nalbuphin, Arzneimittelwechselwirkungen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving zolmitriptan. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (Fachinformation zu Tramadol, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (Fachinformation zu Tramadol und Paracetamol, Warnhinweise und Vorsichtsmaßnahmen)

The onset of symptoms usually rapidly occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Medication Overuse Headache Overuse of acute migraine drugs (e.g. ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Medication Overuse Headache Overuse of acute migraine drugs (e.g. ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fachinformation zu Phentermin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including zolmitriptan, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions ( 7.5 )] . (Fachinformation zu Zolmitriptan, Warnhinweise und Vorsichtsmaßnahmen)